Page
%P
-
Article
A targeted treatment with off-target risks
It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these ...
-
Article
Open AccessClonal evolution in patients with chronic lymphocytic leukaemia develo** resistance to BTK inhibition
Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolut...